Autopsy report · NCT03091491

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

“Slow recruitment due to general pessimism for immunotherapy in NSCLC, availability of alternative therapy and clinician's choice to put patient on immunotherapy outside of trial setting.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 7 months before it stopped.
• 31 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Cancer Centre, Singapore

Sponsor type

University, hospital or other

Conditions

Non-Small Cell Lung Cancer

Interventions

Ipilimumab; Nivolumab

Participants

31

Sites

3

Countries

Singapore

Trials that died the same way

• Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
  “Sponsor decision due to low patient recruitment caused by the change in the treatment landscape of NSCLC.” (67% match in meaning)
• Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain
  “The clinical trial has ended prematurely due to low patient recruitment” (62% match in meaning)
• TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors
  “slow recruitment (only 8 patients recruited and treated until 12/2012)” (60% match in meaning)
• A Study Evaluating Bacillus Cereus in the Prevention of Afatinib-associated Diarrhea
  “Participants have better treatment selection, resulting in a slow recruitment.” (58% match in meaning)
• Catheter Ablation Versus Thoracoscopic Ablation to Patients With Permanent Atrial Fibrillation
  “Patients with permanent AF are seldomly symptomatic enough to justify intervention. We decided to stop inclusion due to low recruitment rate.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.